Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Endothelial GDF15 deficiency enhances barrier function and mitigates pulmonary fibrosis
Kristen Raffensperger, Marta Bueno, Brian J. Philips, Megan Miller, Máté Katona, Shuai Yuan, Adriana Estrada-Bernal, Byron Chuan, Pavan Suresh, Stephanie Taiclet, Scott Hahn, Yingze Zhang, Jonathan K. Alder, Seyed Mehdi Nouraie, Daniel J. Kass, Oliver Eickelberg, Adam C. Straub
Kristen Raffensperger, Marta Bueno, Brian J. Philips, Megan Miller, Máté Katona, Shuai Yuan, Adriana Estrada-Bernal, Byron Chuan, Pavan Suresh, Stephanie Taiclet, Scott Hahn, Yingze Zhang, Jonathan K. Alder, Seyed Mehdi Nouraie, Daniel J. Kass, Oliver Eickelberg, Adam C. Straub
View: Text | PDF
Research Article Cell biology Pulmonology Vascular biology

Endothelial GDF15 deficiency enhances barrier function and mitigates pulmonary fibrosis

  • Text
  • PDF
Abstract

Pulmonary fibrosis is frequently accompanied by pulmonary hypertension, which can occur disproportionate to the extent of fibrosis, suggesting a fibrosis-independent vascular remodeling process. Here, we demonstrated that plasma growth differentiation factor 15 (GDF15) is elevated across diverse fibrotic lung disease subtypes and correlates with markers of elevated right heart pressures but not pulmonary function indices, indicating a possible link to endothelial cell dysfunction. To investigate the import of endothelial GDF15 as a modifier of lung fibrosis pathogenesis, we generated endothelial cell–specific Gdf15-KO mice, which showed protection from bleomycin-induced lung injury and fibrosis, with preserved lung function. RNA-seq of human pulmonary microvascular endothelial cells revealed altered expression of barrier-regulatory genes in GDF15-deficient endothelial cells compared with controls. Functional studies confirmed that GDF15 knockdown attenuates thrombin-induced barrier disruption by reducing cytosolic Ca2+ responses. Together, these findings implicate endothelial GDF15 as a modifier of vascular permeability and Ca2+ signaling and a contributor to lung injury and fibrosis.

Authors

Kristen Raffensperger, Marta Bueno, Brian J. Philips, Megan Miller, Máté Katona, Shuai Yuan, Adriana Estrada-Bernal, Byron Chuan, Pavan Suresh, Stephanie Taiclet, Scott Hahn, Yingze Zhang, Jonathan K. Alder, Seyed Mehdi Nouraie, Daniel J. Kass, Oliver Eickelberg, Adam C. Straub

×

Figure 5

GDF15 Knockdown is associated with decreased change in permeability in response to insult, at least in part due to decreased cytosolic Ca2+.

Options: View larger image (or click on image) Download as PowerPoint

GDF15 Knockdown is associated with decreased change in permeability in ...
(A–D) Electric cell-substrate impedance sensing (ECIS) on HPMVECs. Cells underwent knockdown with siRNA for 48 hours followed by serum starvation for 4 hours prior to the initiation of ECIS. (A) Average resistance over time, normalized to baseline resistance. Each run was performed in quadruplicate; each condition is an average of 8 runs. Thrombin treatment at time = 0 seconds. (B) Baseline resistance of siNT- and siGDF15-HPMVECs, normalized to siNT (n = 12 per condition). (C) Maximum change in resistance following thrombin treatment, presented as a percentage of baseline resistance (n = 8 per condition). (D) Recovery of resistance following the maximum drop in resistance with thrombin treatment, presented as a percentage of total initial resistance drop (n = 8 per condition). (E and F) Thrombin-induced FITC-albumin diffusion across a monolayer of siNT- and siGDF15-HPMVECs. (E) FITC-albumin concentration in plate well at 300 minutes. (F) Permeability index = [X – c] / [m – c] × 100, where X, c, and m are the concentration of FITC-albumin in the wells below treated cells, untreated cells, and acellular membranes, respectively. (G–J) Epifluorescence Ca2+ imaging analysis of HPMVECs 48 hours following siRNA-mediated GDF15 knockdown. (G) Representative traces of cytosolic Ca2+ levels in HPMVECs over time, showing responses to thrombin stimulation. Sample sizes: NT, n = 244 cells; siGDF15, n = 261 cells. Data were pooled from 3 independent experiments. (H) Maximum cytosolic Ca2+ levels following thrombin stimulation. (I) Time to reach maximum Ca2+ response relative to thrombin application. (J) Rate of change in Ca2+ level following thrombin stimulation, calculated as the slope of the initial response. Data were analyzed using the Mann-Whitney U test (B–D and H–J); Welch’s t test (E). Data are presented as mean ± SEM unless otherwise indicated.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts